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The advent of preclinical research scanners for in vivo imaging of small animals has
added confidence into the multi-step decision-making process of radiotracer discovery
and development. Furthermore, it has expanded the utility of imaging techniques
available to dissect clinical questions, fostering a cyclic interaction between the clinical
and the preclinical worlds. Significant efforts from medicinal chemistry have also made
available several high-affinity and selective compounds amenable for radiolabeling, that
target different receptors, transporters and enzymes in vivo. This substantially increased
the range of applications of molecular imaging using positron emission tomography
(PET) or single photon emission computed tomography (SPECT). However, the process
of developing novel radiotracers for in vivo imaging of the human brain is a multi-
step process that has several inherent pitfalls and technical difficulties, which often
hampers the successful translation of novel imaging agents from preclinical research
into clinical use. In this paper, the process of radiotracer development and its relevance
in brain research is discussed; as well as, its pitfalls, technical challenges and future
promises. Examples of successful and unsuccessful translation of brain radiotracers will
be presented.
Keywords: novel radiotracer, translational, brain, animal research, development and discovery
INTRODUCTION
Single photon emission computed tomography (SPECT) and positron emission tomography (PET)
rely on the in vivo detection and quantification of the radiotracer distribution and binding to
a specific biological target in the living body (Salvadori, 2008). These techniques are at the
leading edge of molecular imaging and allow for exceptional target specificity and high sensitivity
(Haberkorn and Eisenhurt, 2005; Salvadori, 2008; Kemp et al., 2010). PET and SPECT imaging is
based on the radiotracer principle, which states that the radiotracer does not alter or perturb the
biological system under investigation. This is only possible when the injected mass of a radiotracer
occupies a small percentage of the target, i.e., the microdosing principle (Ruth, 2009). Radiotracer
imaging allows for studies investigating neurotransmission, metabolism, regional cerebral blood
flow and pharmacology in vivo. Consequently, PET and SPECT imaging can assist in diagnosing
multiple neurodegenerative and neuropsychiatric disorders. They also provide imaging biomarkers
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to track disease development and monitor the effects of
drugs on disease progression. Finally, radionuclide molecular
imaging techniques can be used to determine optimal
dosing for new drugs via microdosing experimental set-
up and can aid with accelerating the implementation of
personalized medicine (Brooks, 2005; Agdeppa and Spiker, 2009;
Van de Bittner et al., 2014).
Despite the tremendous potential of PET and SPECT imaging,
only a limited number of central nervous system (CNS) targets
are currently used in humans; yet there are thousands of potential
brain proteins not yet explored. This limited availability may
in part be explained by the wide range of ever-growing, strict,
criteria that must be fulfilled prior to radiotracer regulatory
approval and by the empirical nature of radiotracer discovery
(Brust et al., 2014; Van de Bittner et al., 2014). In this review,
different aspects associated with brain radiotracer discovery
and development will be discussed. Suggestions of alternative
approaches to improve the flow through the pipeline will be
also provided, alongside examples of radiotracers successful and
unsuccessful in their translation to human research.
THE PROCESS OF RADIOTRACER
DISCOVERY AND DEVELOPMENT
Despite the similarities between drug and radiotracer discovery
and development processes, imaging agent development has the
flexibility to aim at investigating functional and non-functional
targets, as long as they play a role on a given disorder or
mechanism of interest and meet imageability requirements
(Agdeppa and Spiker, 2009). Unfortunately, the relatively small
market sizes for radiotracer commercialization compared with
the drug market, together with radiolabeling constrains and
regulatory/intellectual property challenges, represent restrictions
to the innovation potential in radiotracer discovery and
development. In fact, based on 2004 estimates, the total
imaging market was only 1% of the total therapeutic market
(Nunn, 2006a). This demonstrates that the majority of the
radiotracers developed will fall into a small/specialty market size.
Furthermore, in 2006, it was estimated that a diagnostic imaging
agent takes ˜8–10 years to develop at a cost of between $100 and
$150 million with a potential return in sales of only $200–400
million per year, even for highly used diagnostic agents, such
as the nuclear cardiology radiotracer CardioliteTM, Lantheus.
This value was gained through associated costs from therapeutic
drug development as there were not publicly available data
at this time on costs for developing imaging agents (Nunn,
2006b). Conversely, costs to develop a novel therapeutic drug
are around $850 million over 14 years with a potential return
of up to as much as $3.4 billion (Nunn, 2006a,b). Later, in
Zimmermann (2013) estimated the cost of a conventional drug
development at €82–300 million over 10–15 years; while the
development of novel radiotracers for diagnostic purposes was
calculated to be €20–60 million over 7–9 years (Figure 1).
However, this is a conservative measure looking at money
invested in a successful candidate not taking into account the
investment in failed candidates or candidates that did not make
it to completion. If the cost of investment in research into
unsuccessful targets was included this figure could be as much
as 300% higher (Zimmermann, 2013). In March, Wouters et al.
(2020) reported that when accounting for the costs of failed
drug trials (between 2009 and 2018), the mean investment was
$1,335.9 million. Analysis of the success rate of new drugs per
stage of development, excluding regulatory approval, shows that
the lowest success is achieved at the preclinical stages with only
∼30% success rate. This is lower than first in human success rate
that averages at ˜75% (Takebe et al., 2018). It is possible that the
drop in development costs of successful drugs and radiotracers
relates with improvement of preclinical methods, which in the
case of PET/SPECT imaging might stem from the development
of dedicated preclinical imaging platforms. Notwithstanding, the
overall cost (i.e., corrected for failed candidates) has not reduced
with time. From these data, it is clear that the commercialization
of diagnostic imaging agents will not generate the same return
as pharmaceutical drugs. Thus, partnerships between academia,
the pharmaceutical industry and imaging companies improves
the viability of radiotracer discovery and development in light
of the increasing demand for personalized medicine. Over the
years, the academic community has been invaluable to explore
new high risk/high gain areas; demonstrating the feasibility of
new imaging approaches. Unsurprisingly, academia has been
credited for the majority of PET and SPECT radiotracers
discovery to date. In turn, industry can facilitate the route
to commercialization for radiotracers discovered in academia
(Agdeppa and Spiker, 2009). Furthermore, partnering between
pharmaceutical companies, imaging companies and academia
can allow for the conversion of failed therapeutic agents
into radiotracers. Abandoned drug candidates and families of
compounds, which failed due to toxicity or short biological half-
life, can sometimes be repurposed as PET or SPECT radiotracers.
This is due to the radiotracer principle allowing for the safe use of
very low (picomolar) concentrations of compounds that are toxic
at higher concentrations. Furthermore, the rapid clearance of a
given compound, which is suboptimal for drug candidates, may
be suitable and even desirable, for a PET or SPECT radiotracer
(Willmann et al., 2008).
The process of radiotracer discovery and development has
been described in various ways, however, one aspect of this
process is consistent across the field: developing radiotracers is
a multidisciplinary iterative process. Each stage of the process
can feedback to a prior stage and/or input the subsequent
stage (Salvadori, 2008; Agdeppa and Spiker, 2009; Barth and
Need, 2014; Van de Bittner et al., 2014). Below we provide an
overview of the key stages in the process of radiotracer discovery
and development.
Evaluation of Market Opportunities and
Prioritization of Research Questions to
Target
At early stages of radiotracer discovery, multiple factors must be
considered beyond the scientific challenges alone (Figure 1). It
is important to understand from the outset how the radiotracer
would be used and then established predefined performance
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FIGURE 1 | Overview of radiotracer discovery and development pipeline. Main steps in the radiotracer discovery and development pipeline, including typical
development costs and timelines for development of a successful radiotracer. A strategy to accelerate the process of radiotracer development involves removal of
the in vitro testing of the radiolabeled compound and instead progress with the radiolabeled compound straight into in vivo testing.
criteria required for success. For example, one could ask whether
the development of a novel radiotracer for a given target would
enhance the ability to image such target by improving target:non-
target ratios, reducing off target binding or kinetics in vivo. For
previously unexplored targets, it would be important to provide
convincing evidence that the novel radiotracer will specifically
label the target or mechanism that they are designed to measure
(Agdeppa and Spiker, 2009).
Given the expensive and time-consuming nature of
radiotracer discovery and development, which ultimately
culminates with a small/specialty market, it is also important
to perform a “market search” at the inception of radiotracer
discovery. Obtaining insights from physicians can be useful to
understand the need for a given imaging tool in clinical practice
or research. In short, if imaging with a radiotracer for an unmet
clinical need would not be “prescribed,” then the development
of such radiotracer may be unnecessary. In the basic research
context, which accounts for the majority of these PET and
SPECT imaging, the utility of a radiotracer can be difficult
to anticipate. Potential use can be appraised by discussing
this among colleagues, preclinical scientists and experts from
pharmaceutical companies, in order to determine preclinical use
and human translational potential of a given radiotracer (Van de
Bittner et al., 2014). Commercialization potential is important
when selecting projects and in practice; technically feasible
projects may not be a priority due to a limited potential return
on investment (Nunn, 2006a). A careful evaluation of the market
size may also be driven by current/future install bases in clinical
use and modality constrains. For example, SPECT equipment
is more widely distributed and numerous in comparison with
PET (around 12 530 multi-head SPECT scanners vs. around
1000 PET scanners in the United States of America in 2008)
(Agdeppa and Spiker, 2009). Thus, the development of a novel
SPECT radiotracer might be preferred over a PET radiotracer if
the SPECT imaging performance is adequate. This is especially
true as the physical limits of PET and SPECT detection are
approached in the clinical setting as they have been approached
in the preclinical setting (Mariani et al., 2008; Seo et al., 2008;
Ruth, 2009). For example, in the preclinical setting, small animal
SPECT scanners have higher resolution than PET scanners,
although this comes at the expense of relatively lower sensitivity
(de Kemp et al., 2010; Koba et al., 2013). PET is arguably superior
to SPECT in regards to being able to directly measure the
attenuation effect of the object being viewed; as well as having
a higher resolution and accuracy in quantitative assessment
of regional concentrations of a radiotracer (Alavi and Basu,
2008; Ruth, 2009). The higher sensitivity gives PET the ability to
measure targets with lower expression. However, PET does still
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have limitations and challenges. Short-lived PET radionuclides,
such as 15O and 11C, require a cyclotron in close proximity to
the PET scanner. This may limit widespread market distribution,
but it can be advantageous during early stages of radiotracer
discovery and development as it will be detailed below. PET
scanning also incurs higher costs in comparison with SPECT
scanning (Ottobrini et al., 2006; von Schulthess and Burger,
2010). Targeting specific molecules so that they can be easily
labeled for both PET and SPECT imaging should be considered
in the early stages of radiotracer design in order to reach users in
both modalities. This keeps options open and can save time and
money in long term development.
From a commercialization point of view, similarly to
therapeutic drugs, knowing the intellectual property (IP)
landscape before project conception can help identify
opportunities and competition. It is important to be up to
date on the status of technology, other applicable imaging agents
and non-imaging biomarkers, regardless of the imaging modality.
For example, magnetic resonance imaging (MRI) research is
improving endogenous signal without the use of contrast agents.
Blood biomarkers and non-imaging biomarkers are other forms
of competition and could limit the use of novel imaging agent,
although these diagnostics lack spatial information that can be
obtained with imaging. If a cheap blood test can give the same
information as an expensive time consuming scan then it is
unlikely that it will be adopted in the clinical setting. These
aspects are important to consider, especially due to the long
times associated with the development of novel radiotracers.
Moreover, consideration of the impact of a novel radiotracer on
health economics, in light of the reimbursement issues, may be
valuable when aiming at commercialization of a novel radiotracer
(Agdeppa and Spiker, 2009). Alternative approaches, less focused
on the commercialization of the novel radiotracer, have suggested
to start the brain radiotracer development program based on
assessing an unmet medical need or based on an expectation in
human disease imaging (Van de Bittner et al., 2014).
In summary, when initiating the journey of radiotracer
discovery and development, the researcher must look beyond
purely the scientific scope and should address important
questions. If the purpose of that radiotracer development is to
attract investment and lead to commercialization: (1) is there a
market or a medical need that justifies the development of this
radiotracer?; (2) will the quality of the science and technology
behind the new molecule be attractive to an investor?; (3) is
it feasible and will it comply with regulations?; and (4) in
this limited competitive landscape, will the novel radiotracer
stand a chance? An example of a recently developed successful
radiotracer with potential to have wider impact in the field of
brain research and clinical imaging is 18F-MNI1126, a radiotracer
targeting the synaptic vesicle glycoprotein 2A (SV2A) (Mercier
et al., 2017; Constantinescu et al., 2019).
Target Identification
Traditionally, therapeutic drug targets have an important
mechanistic effect in disease processes, such as, inhibiting the
target may alter/reduce disease severity or progression (Pritchard
et al., 2003). An important difference between therapeutic drugs
and diagnostic radiotracers’ target identification step is that the
latter can be developed for targets that play an important role in
a given disease, yet have no functional effect in modifying disease
processes. A pivotal example of these so called “non-functional”
targets is amyloid imaging, where structural proteins are targeted
(Klunk et al., 2004). This means that a radiotracer target needs
only have altered expression, occupancy or function in a given
disorder, resulting in a wide range of potential targets for in vivo
imaging, which in turn will allow for a given radiotracer to
be applied to investigate several different medical or biological
questions (Agdeppa and Spiker, 2009; Van de Bittner et al., 2014).
To assist with the target identification during radiotracer
discovery, it is also important to consider the location and
amount of target assessable for high quality in vivo imaging. An
essential property for in vivo imaging using radiotracers is the
concept of binding potential (BP), which provide a measurement
of radiotracer-target interaction as a function of the total target
density (Bmax) and the radiotracer binding affinity (KD). The
suggested ideal BP values for in vivo imaging in the literature
can vary considerably from 1.5 (Barth and Need, 2014) up to
10 (Patel and Gibson, 2008). Some have proposed, as a rule of
thumb, that a BP of 5 is a suitable value for quantitative PET
imaging, especially in the clinical setting where kinetic modeling
techniques are not always available (Van de Bittner et al.,
2014). When assessing which target to tackle during radiotracer
discovery, it is possible to estimate the ideal KD value for the
prospective candidate radiotracer from the known Bmax. When
the Bmax is unknown, it can be measured using autoradiography,
binding assays or quantitative immunohistochemistry methods.
In vivo, BP can be expressed in three different forms depending
on the reference used, BPND, BPF , and BPP. BPND refers to
the ratio of radioligand specifically bound to its target vs the
amount binding non-specifically (the non-displaceable amount).
BPF refers to the ratio of specifically bound radiotracer to free
fraction and BPP refers to the total concentration in the plasma
that is available (excluding ligand irreversibly bound to plasma
proteins) (Innis et al., 2007). Examples of brain SPECT and
PET radiotracers previously developed and correspondent BPND
values are presented in Table 1 below.
Although the majority of brain radiotracers developed to
date are small molecules that interact with transmembrane
receptors and transporters, other targets are amenable for
in vivo imaging using PET and SPECT. Some radiotracers can
serve as subtracts for enzymes (a prominent example is 2-
deoxy-2-[18F]fluoroglucose) (Van de Bittner et al., 2014) or
can bind to protein aggregates, most notably amyloid and
tau proteins (Agdeppa and Spiker, 2009; Nordberg, 2014).
Furthermore, radiotracers targeting nuclear receptors have also
been investigated. These require penetration of the cell nucleus
by the radiotracer (Wang et al., 2014). Radiotracers designed to
bind to a transmembrane protein, including G-protein coupled
receptors, may have to compete with native ligands or allosteric
modulation. This means that variations in the endogenous
ligand concentrations can impact image quantification of
receptor density in vivo; setting strict requirements for the
candidate radiotracer KD value. Furthermore, transmembrane
receptors have regulatory mechanisms, such as homo- or
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TABLE 1 | Examples of brain SPECT and PET radiotracers previously developed and associated BPND values in healthy humans.
Radiotracer Target (high to low density) BPND References
123 I-Iomazenil GABA receptors 12.50 ± 0.05 (n = 10) Abi-Dargham et al., 1994
123 I-(R,R)l-QNB mACh receptors 4.85 (n = 11) Norbury et al., 2004
123 I-5-IA85380 α4β2-nACh receptors 4.43 ± 0.06 (n = 6) Fujita et al., 2003
123 I-β-CIT Dopamine transporters 6.66 ± 1.54 (n = 5) Laruelle et al., 1994
11C-Raclopride D2/3 receptors 2.19 ± 0.18 (n = 40) Berry et al., 2018
123 I-IBZM D2/3 receptors 0.86 ± 0.11 (n = 10) Meyer et al., 2008
11C-DASB Serotonin transporters 2.68 ± 0.68 (n = 5) Ginovart et al., 2001
123 I-ADAM Serotonin transporters 1.62 ± 0.57 (n = 7) Yang et al., 2008
11C-PK11195 TSPO 1.60 ± 0.40 (n = 13) Kropholler et al., 2005
11C-PIB β-amyloid plaques 0.11 ± 0.15 (n = 13) Tolboom et al., 2009
18F-FDDNP β-amyloid plaques 0.05 ± 0.03 (n = 13) Tolboom et al., 2009
BPND reduces as a function of target density and radiotracer affinity (e.g., dopamine receptor, serotonin transporter and β-amyloid plaques ligands). The results also
depend on method of quantification used, i.e., kinetic modeling with or without input function (details in sections below). Legend: α4β2-nACh receptor = alpha-4 beta-2
nicotinic acetylcholine receptor; mACh receptors = muscarinic acetylcholine receptors; D2 receptors = dopamine type 2 and 3 receptors; TSPO = 18 kDa translocator
protein.
heteropolymerization and internalization (Ferré et al., 2014);
these can represent unexplored avenues in the development
of new therapies (George et al., 2002), but directly impact
the radiotracer kinetics and binding affinities in vivo. Some
radiotracers developed to image the 18-kDa translocator protein
(TSPO) are also influenced by a genetic polymorphism that
leads to differences in binding affinity within the population
(Owen et al., 2012). If a novel target has a known potential
for genetic polymorphisms, it is important to consider potential
effects of genetic polymorphism on radiotracer binding, and
thus imaging. Although, interestingly, the TSPO radiotracer
11C-PK11195 binding does not seem to be affected by the
genetic polymorphism (Owen et al., 2010; Owen et al.,
2011). This recent observation of genetic polymorphisms
impacting radiotracer binding highlights another new feature
to consider when selecting the target for radiotracer discovery
(Figure 2, Case study 1).
Another important consideration while discovering novel
radiotracers is to understand the error associated with the
imaging technique to be use. Typically for any PET and SPECT
radiotracers this is represented by the intra-subject test-retest
variability. The majority of brain radiotracers have test-retest
results of less than 15% [see for example (Abi-Dargham et al.,
1995; Seibyl et al., 1996; Booij et al., 1998; Varrone et al., 2000;
Catafau et al., 2005; Laere et al., 2013; Barret et al., 2014b; Tavares
A. et al., 2014)], meaning that when investigating longitudinal
changes in either target density or receptor occupancy in a
single-subject, observed changes must exceed 15% in order to
be successfully imaged. Various outcome measures are used
to quantify test-rest variability. BPND is a preferred outcome
measure but is not always possible to measure as it requires
dynamic imaging data from radiotracers that have reversible
binding kinetics and, depending on the target of interest, can
also require invasive arterial blood collection for kinetic modeling
analysis when a reference region devoid of binding is not
available (Innis et al., 2007). BPND from distribution volume ratio
(DVR), calculated from VT , also requires arterial input function
data. The total volume of distribution (VT) has also been used
for quantification of test-retest variability and as an outcome
measure in some cases, such as, in the measurement TSPO
radiotracers concentration in the CNS (Sandiego et al., 2015; De
Picker et al., 2019). VT also requires dynamic imaging protocols
and the use of arterial input function or, even possible, image
derived input function. Standard Uptake Value Ratio (SUVr)
is also used in some cases such as for amyloid radiotracers
(Knešaurek et al., 2018). For estimation of SUVr, static imaging
protocols are sufficient.
Despite all the considerations given during target
identification, the most practical and commonly used approach
in finding potential radiotracers is to identify high-affinity
ligands with known structure-activity relationships. These
are often discovered through drug development programs;
although highly novel targets without known ligands can
also be pursued in radiotracer discovery. Highly novel targets
without known ligands can, however, be time and cost-intensive,
as various compound libraries need to be developed and
screened iteratively. Such “risky” targets, therefore, must have
a high Bmax and demonstrate a significant percentage change
in density or occupancy relating to the research or clinical
question being addressed, in order to be worth the input of
radiotracer development.
In summary, it is important to investigate which target(s) play
an important role in a given disease and can also be imaged
using PET or SPECT (considering, for example, the test-retest
variability of the technique). Targets that play important roles in
multiple disorders can broaden the range of applications of the
novel radiotracer candidate thus make more attractive targets.
Suitable target density for high quality in vivo imaging should be
evaluated and the researcher should also pinpoint the desirable
affinity of the novel candidate radiotracer at this stage (Figure 1).
Design and Selection of Lead
Radiotracer Candidate
It is tempting to start the process of radiotracer discovery by
targeting existing therapeutic drugs, however, it is important to
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FIGURE 2 | Case study 1: Imaging the 18kDa translocator protein (TSPO), a “moving target” over the past three decades. The development of novel TSPO
radiotracers suffered from high degree of attrition over the years (1–3). First there was the renaming of the target, in recognition of the wider functions of this protein.
Then the identification of a genetic polymorphism (rs6971) capable of impacting on radiotracer binding in humans (2nd generation, 2nd gen., radiotracers). Alongside
these discoveries came the recognition that TSPO has at least three binding sites and can be expressed in a monomer or a polymer configuration depending on the
organ or disease process under investigation. Furthermore, limited characterization of the TSPO expression in various cell types decades ago has created a delayed
realization that TSPO PET/SPECT imaging was always directed toward understanding TSPO molecular changes rather than cell changes. All these serendipitous
findings at the first stage of the radiotracer development pipeline (target identification) have impacted on the development of novel and successful TSPO radiotracers
(1 and 2). Despite these difficulties, through a series of compound libraries from 1st generation (1st gen.) radiotracers, like 11C-PK11195, to 3rd generation (3rd gen.)
radiotracers like 11C-ER176 and 18F-LW223, it was possible to resolve the target identification issue, while improving radiotracer properties, such as reduction of
non-specific binding (NS) and convenient labeling with fluorine-18 (3). Red and blue text indicates limitations and advantages of each example radiotracer displayed
in row 3. HC, healthy control brain. TSPO structure taken from Selvaraj and Stocco, Trends in Endocrinology and Metabolism, 2015, 26(7):341.
be aware of the negative aspects associated with this choice.
For example, therapeutic drugs aim for a sustained target-
engagement after one single administration, but this can be
unsuitable for radiotracer imaging; resulting in radiotracers with
slow kinetics. 18F-F13714 is an example of a brain radiotracer
with slow kinetics. It was developed as a serotonin type 1A
(5-HT1A) receptor agonist radiotracer, however, it was found
to have such high affinity that its binding resulted in quasi-
irreversible kinetics (Tavares et al., 2013; Yokoyama et al., 2016).
This sustained binding maybe useful for drugs, however, is sub-
optimal for a radiotracer, as it makes quantification difficult
using traditional kinetic models that assume reversible Michaelis-
Menten kinetics (Innis et al., 2007). Furthermore, it is important
to consider the fact that radiotracers require high brain/plasma
ratio and should have low non-specific binding, two factors that
can at times be less pressing for therapeutic drugs, where it is not
infrequent to have a drug able to bind to several targets in the
brain. An example of a non-selective radiotracer is the SPECT
iodinated analog of Siponimod (a licensed drug for treatment
of Multiple Sclerosis), 123I-MS565, which binds to two types
of sphingosine-1-phosphate receptors (S1P1 and S1P5) (Tavares
A. et al., 2014). It is useful for the use in studying the effects
of Siponimod, however, is of limited use when trying to label
and track changes in one receptor type in the CNS or to try
and establish the role of one of the receptor types in disease
development and progression.
De novo radiotracer synthesis is another route for lead
candidate selection during radiotracer discovery. This route can
Frontiers in Neuroscience | www.frontiersin.org 6 October 2020 | Volume 14 | Article 871
fnins-14-00871 October 1, 2020 Time: 12:14 # 7
Shaw et al. Rapidly Translating Radiotracers to Humans
be even more iterative than the approach described in the
above paragraph. This is particularly true for novel radiotracers
that target complex mechanisms or use non-traditional (non-
small) compounds, as in vitro screening methods would be
more limited in predicting their in vivo performance. In
these cases, conducting simple animal model studies early
could provide information and help to optimize the novel
radiotracer candidates’ performance in vivo. Feedback from
preclinical scientists to the chemists can be used to improve
the radiotracer’s structure before moving into more rigorous
preclinical studies, and if successful, clinical studies (Agdeppa
and Spiker, 2009). Another approach to improve the likelihood
of discovering high-affinity, brain penetrant molecules during
de novo synthesis of CNS radiotracers includes the concurrent
synthesis of compounds with different chemical scaffolds, as
well as, scaffolds that offer several sites for easy substitution
with various functional groups. Furthermore, when developing
compound libraries it is important that the synthesized molecules
have relatively minor deviations in chemical structure, as
additions of small chemical groups can significantly affect
the radiotracer in vivo kinetics and binding properties [see
for example, Stevenson et al., 2010; Seo et al., 2014 and
Figure 3, Case Study 2).
Regardless of the approach used to start the novel radiotracer
design process, at this stage, it is important to consider the
development of compounds with a facile labeling site with
the potential to be radiolabeled across multiple derivatives
(Van de Bittner et al., 2014). Using the same labeling site
across various derivatives would allow for minor changes in
the radiolabeling method between molecules, saving time and
money while developing novel radiotracers. The radionuclides
to be used for radiolabeling should also be considered during
radiotracer design. For PET imaging, the use of carbon-11 (11C),
nitrogen-13 (13N) and oxygen-15 (15O), which are isotopes of
endogenous elements, allows for radiolabeling of target molecules
without changing their chemical properties with 15O-Water,
15O-oxygen and 15O-CO as the examples for 15O. Conversely,
fluorine is not ubiquitous in endogenous biomolecules, may
lead to differences in radiotracer in vivo performance from
derivative biomolecules. This is exemplified by, 11C-DOPA
and L-6-fluoro-18F-FOPA having different decarboxylation rates
in vivo (Torstenson et al., 1999). L-6-fluoro-18F-FOPA can be
successfully used for PET imaging, however, it is far more heavily
metabolized than its carbon-11 counterpart and requires the use
of inhibitors (carbidopa with or without entacapone) to reduce
this metabolism and to gain reliable PET images (Kumakura et al.,
2005; Kyono et al., 2011; Walker et al., 2013). Importantly, the
fluorine-19 (19F) commonly present in drug pharmacophores
may represent a viable strategy to radiotracer discovery, as in
those instances there is only a need for substituting 19F in the
drug with 18F in the radiotracer without changing compound
kinetic properties. When the drug pharmacophores do not
include 19F, one commonly suggested approach involves the
use of 11C for early probe development, i.e., proof-of-concept
de novo radiotracer discovery. Once the hypothesized in vivo
performance using the 11C-labeled radiotracer is confirmed,
18F-labeled analog or other relatively longer-lived radioisotopes
FIGURE 3 | Case study 2: Analog but different. This case study illustrates the
impact of small changes in radiotracer structure on binding kinetics in vivo and
subsequent impact on the translational potential of radiotracers. NKJ64 and
INER were both 123 I-labeled tracers targeting the noradrenaline transporters
(NAT). Both stereoisomers had nanomolar affinity in vitro, but different kinetics
in vivo. The INER compound presented binding in brain consistent with NAT
expression (highest in the midbrain, in particular locus coeruleus – in red),
while NKJ64 had no specific binding to target in baboon brain. SPECT images
co-registered to MRI data for the same baboon. A, anterior; P, posterior;
F, feet; H, head.
(e.g., iodine-123 for SPECT or iodine-124 for PET) would be
explored for subsequent clinical or commercial use. Although
this approach is appealing due to the simplicity of substituting
elemental carbon with its isotope counterpart 11C, from a long
term development perspective it adds cost in the process of
radiotracer development; with potentially no return and/or will
substantially limit the market distribution of the 11C-labeled
radiotracer, as it is estimated that about 90% of PET scanners are
in facilities unable to produce 11C radiotracers with high specific
activity (Klunk and Mathis, 2008). Still, when investigating highly
novel and unexplored targets, this may be the fastest option. It
might also be advantageous to use SPECT radiolabels (e.g., 123I
or Technitium-99m, 99mTc) for biomolecules or drug labeling,
as there is a long history of labeling proteins, nucleic acids and
small molecules with radioiodine (Agdeppa and Spiker, 2009).
Other radionuclides may become more prominent in the future
as universal procedures for radiolabeling intact monoclonal
antibodies (mAbs) or mAbs fragments become available and
increasing interest in using these biomolecules in brain imaging
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is raised within the imaging community (Dongen et al., 2012;
McLean et al., 2012). These include the long-lived positron
emitters iodine-124 (124I, t1/2 of 100.3 h) and zirconium-89 (89Zr,
t1/2 of 78.4 h); and the shorter-lived positron emitters gallium-68
(68Ga, t1/2 of 1.13 h), copper-64 (64Cu, t1/2 of 12.7 h), yttrium-
86 (86Y, t1/2 of 14.7 h) and bromine-76 (76Br, t1/2 of 16.2 h). The
commercially available long life-span 68Ge/68Ga-generator (half-
life 271 days) makes 68Ga a particularly interesting radionuclide
for clinical use, as it can be continuously available even for centers
without a cyclotron and at relatively reasonable costs.
Another aspect to consider during the design of the
radiotracer candidate relates with the development of the
precursor for radiolabeling. The precursor should allow for a
highly reproducible reaction, automation of the radiosynthesis
process (labeling, purification, and formulation) and a
radiochemical yield of the formulated product high enough
to permit human application (Brust et al., 2014). The automation
is useful in various ways, in terms of reproducibility, it minimizes
human error. Importantly, once the radiosynthesis method is
optimized and is fully automated, production of radiotracers
can be scaled-up enabling large scale production for local
use (multiple patients a day) or distribution to different PET
sites (if the radioisotope half-life permits). Several aspects
require consideration when designing candidate radiotracers,
including type of precursor to be used. For example, tin
precursors are sub-optimal for clinical use, because they require
additional quality assurance given the highly toxic nature of
tin. The type of precursor selected will also impact on the
separation method to be used to obtain the final product
(e.g., high performance liquid chromatography or solid phase
extraction). Two excellent reviews have been recently published
detailing PET radiochemistry principles (Brandt et al., 2018;
Pichler et al., 2018).
Identifying the lead radiotracer candidate among a library
of compounds shares similarities with the process of drug
development and includes screening of the affinity for the target,
selectivity, metabolism, lipophilicity and molecular weight/size
(Agdeppa and Spiker, 2009; Pike, 2009; Van de Bittner et al.,
2014) (Table 2). Despite the comprehensive list of characteristics
that hold promise to yield an ideal radiotracer for brain imaging,
the suggested criteria are not a definite recipe for success,
but rather some empirical or observation-based guidelines that
are continuously being refined. In fact, several physicochemical
properties such as Log P, Log D, molecular weight and the
acid dissociation constant (pKa) have been found to correlate
with in vivo behavior to some extent, but are not necessarily
predictive of radiotracer performance in vivo (Van de Bittner
et al., 2014). Thus, even though a substantial emphasis has been
placed in the in silico models and computation for assessment
of physicochemical properties of potential radiotracers for brain
imaging (Clark, 2003; Agdeppa and Spiker, 2009), these methods
do not necessarily concur with the in vivo performance of a
number of radiotracers developed, as has been shown in the
literature (Tavares et al., 2012b; Van de Bittner et al., 2014).
Radiotracer metabolism (discussed further in following
section) is often a major stumbling point encountered during
radiotracer discovery and translational imaging. Although
TABLE 2 | Criteria for passive diffusion of a radiotracer across the
blood-brain-barrier (BBB) and good bioavailability (Lipinski et al., 2001; Clark,
2003; Waterhouse, 2003; Wong and Pomper, 2003; Pike, 2009; Van de Bittner
et al., 2014).
Action Characteristic Requirement
Crossing BBB Molecular weight <450 g/mol
Crossing BBB Polar surface area <60–90 Å
Crossing BBB Number of hydrogen bond
donors
<5
Crossing BBB Sum of nitrogen and
oxygen atoms
<10
Crossing BBB Log P (partition coefficient) <4 (ideal range of
1–3.5)
Crossing BBB Affinity for efflux pumps
(e.g., P-gp)
Minimal
Crossing BBB Affinity for enzymes at the
BBB
Minimal
Crossing BBB Brain uptake (%ID) ≥0.5%
Brain uptake (SUV) >2.0
Metabolism Ionization at physiological
pH
Low
Metabolism Presence of
radiometabolites in brain
Low
Binding to silent sites Binding to plasma proteins Low
Binding to silent sites Non-specific or
non-saturable sites
Low
Binding to target site Kinetics quantifiable in vivo Reversible or not
completely irreversible
Binding to target site Dissociation or inhibition
constants
Nanomolar range
Binding to target site Selectivity High
Binding to target site Specificity High
Radiological safety Whole-body and critical
organ dosimetry
Low radiation dose
P-gp, P-glycoprotein; %ID, % injected dose; SUV, standard uptake value.
radiotracer metabolism in vivo may be hinted during radiotracer
design or radiotracer screening in vitro, metabolism is highly
species-dependent; typically compounds show more extensive
metabolism in lower organisms.
Several methods have been proposed to assist with radiotracer
lead candidate selection early in the process of radiotracer
discovery. These aim to increase the likelihood of success
of a novel brain radiotracer in vivo. These methods include
in silico simulations, in vitro testing, high-performance liquid
chromatography methods and liquid chromatography–mass
spectrometry techniques (Clark, 2003; Agdeppa and Spiker,
2009; Tavares et al., 2012b; Barth and Need, 2014; Van de
Bittner et al., 2014). Nonetheless, there is a growing indication
from the radiotracer development community that progressing
rapidly into in vivo imaging following a short high throughput
screening exercise targeting key properties (affinity, selectivity
and BBB penetration estimation) or even move directly into
radiolabeling and in vivo imaging studies, with subsequent
iterative feedback between preclinical imaging and chemistry,
may be the way forward. In this emerging philosophy, the
lead candidate selection can be reduced to at most a rapid
screening and ranking of molecules prior to radiolabeling, where
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the affinity for the target would be assessed in conjunction
with the biological target density and the likelihood of BBB
penetration would be assessed by a high throughput technique.
To maximize efficiency, during radiotracer affinity experiments,
it is useful to include a known radiotracer targeting the same
process as a control together with the radiotracer library under
scrutiny. This has already been applied in the development of
novel TSPO ligands based on PK11195 structure (Stevenson
et al., 2010) (Figure 2, Case Study 1). Although the specific
ranking order of the compound’s affinity is less central than
their clustering based on chemical structure, it can provide a
starting point to select which cluster of radiotracer candidates to
prioritize for in vivo imaging. Similarly, when ranking candidate
radiotracers for BBB penetration, it is important to include in
the analysis known successful radiotracers. A recently proposed
methodology uses high performance liquid chromatography
for rapid screening and ranking of candidate radiotracers in
terms of permeability, plasma protein binding and compound-
membrane interaction (Tavares et al., 2012b) (Figure 4) and has
been adopted by different research groups working on novel
radiotracer development (Blair et al., 2013; Gilfillan et al., 2013;
Mark et al., 2013; Philippe et al., 2013a,b; Rami-Mark et al., 2013).
This chromatography method uses compound retention time
information to derive permeability, plasma protein binding and
compound-membrane interaction and vs. a calibration curve.
The chromatography outcome measures (permeability, plasma
protein binding and compound-membrane interaction) can then
be used to predict in vivo behavior of the compound using
mathematical equations describing the relationships between
chromatography outcome measures and in vivo measures
(%injected dose in brain and BPND) (Tavares et al., 2012b).
Newer mass spectrometry methods have also been proposed
for estimation of specific and non-specific binding across brain
regions (Barth and Need, 2014). However, the use of unlabeled
compounds makes the measurement of metabolites difficult and
the proposed approach can be labour intensive. It requires
the use of several animals and dissection techniques following
administration of the unlabeled compound, as each animal can
only provide information for a limited number of time points.
In summary, the design and selection of the lead radiotracer
candidate can start by targeting existent therapeutic drugs or
initiating a de novo radiotracer program. During this stage, the
researcher should focus on targeting compounds that would
allow for ease radiolabeling, preferably would allow for labeling
with different radioisotopes for PET or SPECT imaging (keeping
the potential market options open). Once the library of target
compounds has been identified or designed, screening of these
compounds for key properties (affinity and BBB penetration)
must be rapid and simple, with the aim to progress as quickly
as possible to in vivo imaging. Sometimes it might even be
possible to obviate this step all together and move straight into
radiolabeling and in vivo imaging, depending on the level of
information one has on a given molecule (Figures 1, 4).
Preclinical Studies to Evaluate Novel
Radiotracer Candidates
For decades, the affinity, selectivity and binding kinetics of
novel radiotracers have been studied using autoradiography and
binding assay techniques (Udenfriend et al., 1987; Cook, 1996;
Schuck, 1997; Qume, 1999; Lazareno, 2001; Frank et al., 2007).
However, frequently, these approaches lead to novel radiotracers
displaying poor in vivo kinetics and high non-specific binding in
the first round of in vivo imaging, often contributing to the high
attrition rate during radiotracer development. Thus, moving the
novel radiotracer rapidly into small animal in vivo imaging can
FIGURE 4 | Example of high performance liquid chromatography approach that could be used for screening and ranking of radiotracer candidates. Based on
previously published methodology (Tavares et al., 2012b). This chromatography method uses compound retention time information to derive Pm, %PPB and Km.
These chromatography outcome measures can then be used to predict in vivo behavior of the compound using mathematical equations describing the relationships
between chromatography outcome measures and in vivo measures (%injected dose in brain and binding potential BPND). Pm, permeability; %PPB, %plasma protein
binding to human serum albumin; Km, compound-membrane partition coefficient; BBB, blood brain barrier; NS, non-specific binding.
Frontiers in Neuroscience | www.frontiersin.org 9 October 2020 | Volume 14 | Article 871
fnins-14-00871 October 1, 2020 Time: 12:14 # 10
Shaw et al. Rapidly Translating Radiotracers to Humans
accelerate the process of radiotracer discovery and development
(de Kemp et al., 2010; Koba et al., 2013) by removing redundant
steps between compound chemical synthesis and in vivo imaging.
A successful example that came out of this direct strategy,
supported by in vivo imaging at early stages, is 18F-MNI444, a
novel PET radiotracer targeting adenosine-2A receptors (A2A)
in the brain (Barret et al., 2014a; Barret et al., 2015). Preladenant
served as target re-purposed structure for development of this
radiotracer, then precursors for radiolabeling were designed and
synthesized and the new radiotracer immediately tested in non-
human primates (Barret et al., 2014a). The promising results in
non-human primates rapidly prompted the progression of the
compound to humans (Barret et al., 2015). The whole process
took only 4 years.
In fact, imaging studies can allow for the determination of
major radiotracer attributes traditionally determined using non-
imaging methods or in vitro/ex vivo imaging techniques. For
example, in vivo imaging can be used to determine binding
affinity (BP = Bmax/KD, where smaller KD would corresponds
to larger BP for a given target); binding kinetics can be
investigated by quantitative analysis and kinetic modeling of
the obtained time-activity curves; BBB penetration can be
estimated as percentage injected dose in brain; specific binding
can be determined using homologous blocking experiments or
knockout animals; and selective binding can be determined
using heterologous blocking or knockout animals (Kemp et al.,
2010; Koba et al., 2013; Van de Bittner et al., 2014). Nowadays,
kinetic modeling in rodents much as is done in humans
and large animals is becoming more commonplace due to
advances in automatic blood sampling instrumentation (Alf
et al., 2013; MacAskill et al., 2019). This, however, does have
some limitations, namely the fact that it requires expertise in
femoral artery cannulation, a procedure that can only typically
be performed twice in small animals (Warnock et al., 2014). For
those PET/SPECT research sites without access to this blood
sampling technology, manual blood collection is possible and
would enable the use of population-based curves, or image-
derived input functions can be obtained. Although these would
result in quantitative bias vs. the continuous arterial sampling
per experiment (MacAskill et al., 2019), they can still allow
the researcher to quantify PET data and conclude on which
radiotracer candidate is the most promising for translation to
higher species. Furthermore, moving a novel radiotracer from
chemistry directly into in vivo preclinical imaging can also reduce
the likelihood of researchers to overlook useful radiotracers. For
example, the use of autoradiography techniques for assessment
of binding kinetics by varying pre-incubation and washing steps
would be unsuitable in evaluating whole-body biodidistribution
kinetics and metabolism, essential aspects for assuring the success
of a novel radiotracer for in vivo imaging. Similarly, even the
“no wash” autoradiography method proposed for estimation of
specific binding (Patel et al., 2003) would be suboptimal at
evaluating a novel radiotracer performance in vivo (the ultimate
targeted environment). Moreover, the resources allocated for
these type of in vitro/ex vivo experiments require radiolabeling
of the radiotracer, deeming these approaches inadequate for
prospective screening. Consequently, these techniques are
slowly, but consistently, being replaced by preclinical imaging
techniques, which are becoming key translational tools for proof-
of-mechanism and concept studies (Agdeppa and Spiker, 2009;
Van de Bittner et al., 2014) (Figure 1). That said, the use of ex vivo
studies to assess radiotracer metabolism is still unavoidable, given
the need to sample organ tissue and blood for analysis (as
detailed below).
Another important factor that may explain the reasoning
behind using in vivo preclinical imaging methods vs. ex vivo
dissection studies for assessment of radiotracer distribution is
that imaging devices are seen as technical refinements, in line
with the principles of the three Rs (replacement, reduction
and refinement). There are several reasons supporting this
view, including the fact that: (1) in vivo imaging techniques
are less invasive that other techniques; (2) by using the
animals as their own controls, the number of animals to be
sacrificed is reduced and the statistical power is improved,
with consequent scientific benefit; and (3) diagnostic and
therapeutic agents can be developed on identical platforms, thus
providing a unique straightforward translational paradigm. In
fact, small animal imaging has been perceived as an approach
with potential to provide a natural bridge to the clinical
development by the National Institute of Biomedical Imaging and
Bioengineering established by the National Institutes of Health
(Koba et al., 2013).
Preclinical in vivo imaging can be used early in radiotracer
discovery to make modifications of the chemical structure
based on the novel radiotracer kinetic behavior, allowing for a
faster “tailoring” of the most suitable radiotracer candidate. As
discussed throughout this review, moving toward this approach
could enable rapid and successful translation of novel brain
radiotracers to clinical use. Furthermore, preclinical imaging
can alternatively be used later (prior to human studies) to
obtain the complete kinetics of the radiotracer, as well as,
to estimate dosimetry, in order to identify the dose-limiting
organ radiation exposure; information that can be used in the
translation to humans. In fact, the recently developed MOBY
mice phantoms for estimation of radiation exposure using mice
models have made it possible to use preclinical imaging for
dosimetry estimates, easing translation into humans (Larsson
et al., 2007). Although ex vivo biodistribution studies can also
be used to estimate dosimetry, they require at least 4-6 times
more animals, given that each measurement at a given time
point requires sacrificing a group of rodents for tissue harvesting,
vs. dynamic in vivo imaging of multiple points from a single
rodent. The use of preclinical dosimetry for estimation of clinical
radiological safety has been a regulatory requirement for several
years, albeit some recent discussion has questioned its utility
given the first in human studies include dosimetry assessments. It
is possible that the development of highly sensitive scanners, e.g.,
the total-body PET (Cherry et al., 2018), would enable even faster
translation to humans by minimizing concerns around radiation
dose exposure from novel radiotracers.
Given that PET or SPECT radiotracers should not elicit
a pharmacologic effect (owing to the radiotracer principle),
a pharmacodynamics response is not measurable. This means
the burden of proof lies in the ability to correlate the uptake
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with modulated target density. This can be easily accomplished
using in vivo imaging techniques and therapeutics or genetically
modified animals (Agdeppa and Spiker, 2009). Assessment of
radiotracer brain penetration can be accomplished by inspecting
the time-activity curves and expressing the measured signal as
a percentage injected dose over time. The cutoff values for
accepting a radiotracer as suitable for CNS imaging based on
whole-brain uptake are not consensual. Recently, Van de Bittner
et al. (2014) reported the values used in their laboratory to
be 0.1% injected dose (ID)/cc for rats and 0.01% ID/cc for
non-human primates within 5 min of injection. As mentioned
previously, values of brain uptake in rodent and non-human
primate of ≥ 0.5% have also been suggested as a guideline to
yield suitable CNS radiotracers. However history has shown that,
in humans, BBB-penetrant radiotracers developed for in vivo
imaging of the CNS have expressed variable%ID in whole-brain.
For example, 123I-PK1119, 11C-DASB and 123I-Iomazenil had a
peak %ID in whole-brain of around 2.0% (Versijpt et al., 2000),
4.0% (Lu et al., 2004), and 13% (Dey et al., 1994), respectively.
This represents a fairly wide range of radiotracer brain uptake,
highlighting that definitive cutoff limits might be difficult to
implement. This is because %ID values provide little information
about radiotracer kinetic properties and are dependent on a
number of factors, including radiotracer free fraction in plasma
and time of measurement after injection. Still, cutoffs proposed
in the literature, as a result of different groups experience
while developing radiotracers, can be a useful first line guidance
when screening compounds (e.g., by using in vitro methodology
reported in Figure 4 and in Tavares et al. (2012b). Another
method proposed to evaluate radiotracer penetration is based
on the analysis of the standard uptake values (SUVs). This has
the advantage of allowing for comparison across different species
and tissues, as it is a measure normalize to injected dose and
body weight. An SUV value of 1 will correspond to a radiotracer
concentration that would result in uniform distribution of the
injected dose in the whole-body. Typically, a peak SUV > 2 is
generally desirable for brain imaging (Pike, 2009) (Table 2).
Subsequent to demonstrating radiotracer brain penetration,
it is important to assess the degree and length of radiotracer
retention in the brain. For example, evaluating if the radiotracer
has been actively effluxed from the brain. This can be
accomplished by imaging animals pretreated with inhibitors of
active efflux proteins. Active efflux mechanisms show variation
across different species and, similarly to metabolism, can be
difficult to control or predict when translating a radiotracer
from one species to another. In a study comparing three
PET radiotracers in different species, it was found pronounced
differences in the brain and brain-plasma concentrations of 11C-
Verapamil, 11C-GR205171 and 18F-altanserin with lower brain
distribution in rats and guinea pigs compared with humans,
monkeys and minipigs. One of the conclusions of that study
was that compounds found to be P-gp substrates in rodents are
also likely to be substrates in higher species, although this is
not a linear predictor of BBB permeability and the compound
might still be retained in human brain (Syvänen et al., 2009).
In general, the majority of the P-gp substrates are transported
to a lower extent by human P-gp compared with mouse or rat
P-gp (Yamazaki et al., 2001; Ohe et al., 2003; Katoh et al., 2006;
Baltes et al., 2007). However, there are exceptions, for example,
cyclosporin A (Katoh et al., 2006; Baltes et al., 2007).
When a radiotracer candidate displays good brain penetration
and retention, specific binding to the target can be demonstrated
by homologous blocking studies. During these measurements it
is important to consider potential blockade of the radiotracer
binding in peripheral tissues, resulting in increased free
radiotracer in plasma with consequent increase of total brain
uptake relative to control. This effect can be corrected by
normalizing the radiotracer uptake to metabolite-corrected
plasma radiotracer levels or by performing kinetic modeling
analysis of the acquired data. Furthermore, heterologous blocking
studies can be used to evaluate potential off-target binding
and knockout animals can be of value for confirming on-
target binding.
Analyzing the time-activity curves from in vivo preclinical
imaging experiments, can infer the suitability of a radiotracer
for human imaging. For example, if the measured time-activity
curve slope is near zero, this may be indicative of irreversible
binding or very slow kinetics, which is not ideal in vivo.
Conversely, decreases in binding potential during bolus or bolus
plus constant infusion experiments with injection of homologous
or heterologous blocking agents midscan represent measurable
adequate reversible kinetics (Van de Bittner et al., 2014).
Effective radiotracer design can limit potential problems
from troublesome radiometabolites, yet radiotracers resistant to
extensive metabolism over the duration of the PET or SPECT
imaging session are scarce (Pike, 2009). And as mentioned
before, the nature and degree of metabolism varies across
species. For example, the metabotropic glutamate receptor 5
(mGluR5) radiotracer 18F-SP203 (Siméon et al., 2007) is rapidly
defluorinated in the rat brain and blood as well as in monkey
blood, however, shows no defluorination in humans (Brown et al.,
2008). A similar trend has been observed with the serotonin
type 4 receptors (5HT4) radiotracer, 11C-SB207145, that was
successfully translated into humans (Gee et al., 2008; Marner
et al., 2009), yet displayed pronounced peripheral metabolism
in preclinical species. Therefore, it has been argued that the
determination of metabolites in rodents or larger animals (pigs
or monkeys) provides suitable data to inform clinical PET studies.
The argument is that due to the higher surface-to-volume ratio,
the influence of metabolism on the PET quantification of human
data is usually overestimated when investigated in experimental
animals (Brust et al., 2014). Due to the known species differences,
it has been argued that efforts should be made to progress to
first in human studies as quickly as possible and some have
argued that non-human primate preclinical imaging would be
more predictable of radiotracer performance in humans (Van de
Bittner et al., 2014), although this might not always represent
the truth. In fact, for certain complex CNS targets, it might
be that small animal models are more suitable to investigate a
novel radiotracer, despite the potential for a faster metabolism.
Genetically modified rodent models that express human disorder
phenotypes are readily available and produce information that
may not be so easily obtained from non-human primates.
For example, when developing a novel radiotracer targeting
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neuroinflammation or beta-amyloid deposition, conditions that
are not present in a healthy brain, it can be difficult to
judge the novel radiotracer candidate performance without the
use of adequate animal models. Weighing the pros and cons
of using different animal species for radiotracer development
demonstrates why radiotracer metabolism can be considered one
of the parameters most difficult to control during radiotracer
discovery, and the one potentially causing the most attrition
during this process.
Ideally the metabolism of a novel radiotracer would occur
outside the brain and produce less lipophilic radiometabolites,
than the parent radiotracer, with poor brain penetration.
However, this is not always the case. Thus, at times, the rate
at which troublesome radiometabolites cross the BBB into the
brain parenchyma and their affinity for the target determines the
performance of a radiotracer. For example, the presence of non-
troublesome radiometabolites in the brain has been reported for
several novel radiotracers developed to image phosphodiesterases
type 10A (PDE10A) (Celen et al., 2010; Tu et al., 2011; Celen et al.,
2013; Van Laere et al., 2013; Barret et al., 2014b). These studies
demonstrate a region-dependent metabolite fraction profile,
with the highest fraction in the cerebellum and lowest in the
caudate/putamen (the target region) (Celen et al., 2010; Celen
et al., 2013). This suggests that the radiometabolite entering the
brain does not bind to PDE10A and only gives non-specific
signal. Furthermore, signal in the brain from the radiometabolite
seems consistent, low and negligibly reflected in the in vivo
time-activity curves of regions with low densities of PDE10A.
These observations have allowed for the successful translation
of the novel PDE10A radiotracers from preclinical into clinical
research, even with the presence of radiometabolites in the brain
(Barret et al., 2014b).
As stated throughout this review, a multifactorial and
complex issue that causes attrition throughout the radiotracer
development pipeline is species differences. Several views on
this topic have been largely discussed in the literature. Some
defend moving the novel brain radiotracer directly into non-
human primate without small animal imaging, to minimize the
attrition rate when translating to humans. This view is supported
by data demonstrating a close homology between, for example,
amino acid content in P-gp in humans compared with non-
human primates (93% homology between humans and rhesus
monkey, vs. only 85% between human and rat) (Syvänen et al.,
2009). Furthermore, target density in brain might be significantly
different in rat compared with non-human primate and human.
For example, in the non-human primate brain, the density
of noradrenaline transporters (NAT) in the locus coeruleus is
around 220 fmol/mg, while in rodents the NAT density in the
same brain region is around 1500 fmol/mg (Tejani-Butt, 1992;
Smith et al., 2006). Thus, rat brain has seven times more NAT
binding sites than non-human primate brain. This has been
pointed out as one of the potential reasons underlying the
different imaging profile measured with 123I-NKJ64 (a SPECT
radiotracer candidate for imaging of NAT in brain) in rats
compared to baboons (Tavares et al., 2011; Tavares et al., 2012a).
It is worth noting that that the density of NATs in human
locus coereleus is similar to the one measure in non-human
primates (Ordway et al., 1997). Consequently, although rat data
demonstrated that 123I-NKJ64 held promise for imaging of NAT
in brain, data collected in baboons showed a lack of specific signal
in target regions and precluded the translation of this radiotracer
into humans (Figure 3, Case Study 2). Nonetheless, there might
be instances where the use of rodents may be preferred when
developing novel radiotracers. The mouse remains the premier
animal model for biomedical research because mice have a
short reproductive cycle, can be easily genetically modified and
are easy to maintain. Furthermore, there is high homology
between the human and the mouse genomes, which facilitates the
construction of animal models of human disease at a fast rate and
with high specificity (Niu and Chen, 2014). There are multiple
transgenic animals containing mutations for human disease for
with a specific gene has been identified, including for example,
Parkinson’s disease, Huntington’s disease, Alzheimer’s disease,
epilepsy and multiple sclerosis (Furlan et al., 2009; Casteels et al.,
2014). Also, the introduction of the “humanized mouse” models
may serve as a preclinical bridge for translating data from animal
models into humans (Niu and Chen, 2014). Rodent models may
be the best preclinical alternative available when developing novel
radiotracer targeting neuroinflammatory human brain disorders,
such as multiple sclerosis, or brain disorders that result from
abnormal protein accumulation that is not observed in the
healthy brain, given that rodent models are reliable and predictive
models of human disorders. This does not mean that non-
human primate models of brain disorders are not available,
however, they are often chemically- or vector-derived models and
come at a higher cost, which may add to an already expensive
development process. That being said, the use of small animals
in psychiatry is limited, especially when investigating pathways
without homology in rodents, e.g., the expanded prefrontal
cortex of the human brain (Casteels et al., 2014). Furthermore,
the metabolism in lower species such as rodents may not
directly forecast metabolism in humans, as shown on various
publications, because it tends to be faster in rodents compared
with humans. Species differences are unavoidable, however,
as outline above, preclinical radiometabolism studies can still
provide useful information during radiotracer development,
because preclinical studies enable organ collection for direct
quantification of radiometabolism in tissue – something that is
not feasible in humans. Importantly, preclinical rodent studies
often present the “worst case scenario” due to rapid metabolism
of these species and can enable comparative analysis of analog in
a compound library prior to translation to humans.
In addition to the pitfalls and challenges highlighted above, the
majority of the preclinical in vivo imaging studies are conducted
under anesthesia. The list of publications demonstrating the
impact of anesthetic agents on radiotracer uptake and kinetics
is vast [see for example: (Lee et al., 2005; Fueger et al., 2006;
Hildebrandt et al., 2008; Giron, 2009)], so this will not be
discussed in detail here, but it is worth to point out the need to
be aware of this potential confounder when interpreting in vivo
preclinical imaging data. Another important aspect that has
also been extensively reviewed is the need to accurately control
the levels of administered radiotracer mass. If the radiotracer
principle is key to PET or SPECT imaging in human subjects,
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in preclinical imaging it is imperative that radiotracer levels are
controlled owing to the smaller animal body sizes. An example
would be the setoronin type 4 receptor (5-HT4) radiotracers,
11C-SB207145 and 18F-MNI698, where microgram per kilogram
mass doses were sufficient to induce non-negligible receptor
occupancy (Madsen et al., 2011; Tavares A. et al., 2014). These
radiotracers were still useful for preclinical and clinical PET
imaging of 5-HT4 because the molar activity was sufficiently
high, thus respecting the radiotracer principle. However, these
cautionary mass-effect studies highlight the importance of
quantifying and respecting the molar activity limits to enable high
sensitivity PET imaging. With the recent development of total-
body PET human systems (Cherry et al., 2018), the molar activity
limits might be less restrictive owing to a gain in instrumentation
sensitivity, which would in turn require low injected doses of
the radiotracer. Notwithstanding, researchers should always be
mindful of the radiotracer principle, especially when developing
novel PET or SPECT brain radiotracers.
In summary, at this stage of radiotracer development,
controversies arise when discussing which animal species to
use and good arguments from each side of the fence suggest
that a case-by-case analysis is necessary when deciding how
to progress in the radiotracer development pipeline. The use
of non-human primates can provide the most insightful and
“predictive” information prior to human studies, however, there
are instances when investigating specific CNS targets where
the use of genetically engineering rodent models can be more
useful than non-human primates in assessing radiotracer
performance. There is, however, a growing consensual
view that moving straight to in vivo preclinical imaging
and skipping in vitro/ex vivo testing with the radiolabeled
compound is the most efficient way to proceed during
radiotracer development (Figures 1, 5). Importantly, the
process of developing radiotracers is iterative and failure at
some stage can lead back to an earlier stage, as illustrated in
Figure 5.
Proof-of-Concept in Humans
Once a novel radiotracer has passed through preclinical testing
and shows promising results, it will enter the final step
in radiotracer discovery/development, i.e., proof-of-concept in
humans with subsequent clinical trials. To successfully obtain
permission to move a radiotracer from preclinical to clinical use
it is important to transition from a research-grade radiochemical
FIGURE 5 | Flow chart illustrating suggested approach to radiotracer discovery and development. Decision points based on literature reviewed in this paper and
experience in brain radiotracer development. This illustrates the iterative nature of the process and provides guidance on strategies for successful translation of novel
compounds into humans. When possible, repurposing compounds from drug discovery pipelines as potential radiotracer candidates can be advantageous to rapidly
and successfully develop new PET and SPECT radiotracers for imaging the human brain. In case of de novo chemistry, all in vitro testing should be conducted with
the non-radioactive library of compounds. This could be done by employing high throughput screening methods for measuring novel compounds’ physicochemical
properties (e.g., Figure 4) and affinity for target. The removal of in vitro testing of the radiolabeled compound (as per Figure 1) will also further accelerate the process.
Frontiers in Neuroscience | www.frontiersin.org 13 October 2020 | Volume 14 | Article 871
fnins-14-00871 October 1, 2020 Time: 12:14 # 14
Shaw et al. Rapidly Translating Radiotracers to Humans
to a radiopharmaceutical for which higher standards of product
quality must be met (Brust et al., 2014). The list of aspects to
consider during this translational process is long and has been
extensively reviewed elsewhere (Verbruggen et al., 2008; Agdeppa
and Spiker, 2009; Elsinga et al., 2010; VanBrocklin, 2010).
Radiation safety, toxicology issues, quality control, licensing and
regulatory control are some of the aspects to consider. The
regulatory control is often the major bottleneck in the translation
process from preclinical to clinical research and has become
increasingly restrictive over the last two decades. For example,
currently the typical time between the successful radiolabeling
of a novel radiotracer and first human use can vary between 5
and 10 years, while at the beginning of neuroreceptor imaging
with PET or SPECT this transition was much shorter, in the
range of 1–2 years (Brust et al., 2014). Typically the factors
contributing to the limited number of approved radiotracers
can be classified in three major categories: radiotracer discovery
and development, regulatory aspects and clinical development
(VanBrocklin, 2010). Another hurdle in transitioning from
animal research to human studies relies on the fact that the
radiotracer may fail and be deemed unsuitable for in vivo imaging
of the human brain. However, even if the radiotracer is not
further developed into a radiopharmaceutical, it may still find
widespread use in preclinical studies to investigate animal models
of diseases or new drugs. Thus, one should remain optimistic
when discovering and developing novel radiotracers for brain
imaging, as with persistence and ever-improving preclinical
assessment of radiotracers, the translation gap between animal
and human research is rapidly tightening.
Proposed Approach for Rapid
Translation of Radiotracers From Animal
to Human Research
Developing novel radiotracers for brain imaging is a challenging
process, requiring multidisciplinary teams, in order to gather
the knowledge from marketing and target identification, disease-
related biological mechanisms, chemical synthesis, radiolabeling,
and image acquisition and analysis. This process can be lengthy
and costly, and circumventing failure is difficult when translating
from animal research into clinical use. Several approaches and
philosophies have been suggested for improving efficiency of the
radiotracer discovery and development pipeline (Nunn, 2007;
Salvadori, 2008; Agdeppa and Spiker, 2009; Van de Bittner et al.,
2014). An alternative proposed based on the literature reviewed
in this paper as well as on current trends and previous experience
while developing novel radiotracers is presented as a flow chart in
Figure 5.
CONCLUDING REMARKS
Biomarkers can be classified into three classes: type 0 biomarkers
along the continuum of the natural history of the disorder; type
1 biomarkers for detecting therapeutic drug’s mechanisms of
action; and type 2 biomarkers that are equivalent to surrogate end
points (Frank and Hargreaves, 2003). PET and SPECT imaging
target all three types of biomarkers. Hence the potential of
these imaging modalities is phenomenal alongside concept of
personalized medicine, as well as and the key supportive role
they can have in the process of novel therapeutics discovery
and development. The development of novel radiotracers and
subsequent rapid and successful translation into humans is
pivotal to realize the potential of PET and SPECT imaging as
useful biomarkers. This translational process can be optimized
and efficiently shorten with the aim to move into clinical use
as soon as possible. A suggested approach to assist with these
goals has been proposed in this manuscript, essential aspects to
consider when developing novel radiotracers for brain imaging
were highlighted and proposed solutions or alternatives, when
available, were described.
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